This study provides a molecular basis for the tissue selectivity of dihydropyridine calcium channel antagonists between heart and smooth muscle.
Answers are grounded in this paper and cite their sources.
May guide tissue-selective dihydropyridine design; leaves open translation from animal channels to clinical use.
At least four calcium channel subtypes (P, T, N, and L) have now been classified on the basis of their biophysical and/or pharmacological properties. L-type channels, a channel family particularly important to physiological function of the cardiovascular system, are identified by their slow voltage- and calcium-dependent inactivation as well as their sensitivity to dihydropyridine (DHP) calcium channel antagonists. In this study, we report the results of experiments in which we have measured the DHP modulation of recombinant calcium channel activity in cells transfected with alpha 1 subunits of cardiac and smooth muscle L-type calcium channels. We find subunit-dependent differences in the voltage and concentration dependence of channel modulation. Our results provide evidence for a molecular basis for DHP sensitivity of heart and smooth muscle calcium channels and, additionally, indicate that, even within one family of calcium channels, slight differences in channel structure can cause marked differences in channel pharmacology.
No takes yet. Share an insight, caveat, or question.
Welling et al. (1993) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: